Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in DLE and SLE
NCT03159936Phase 1Terminated
- Sponsor
- Tufts Medical Center
- Start
- Apr 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tofacitinib oral solution in discoid lupus erythematosus (DLE), sponsored by Tufts Medical Center. Primary endpoint: Cutaneous Lupus Erythematosus Disease Area and Severity Index at 24 weeks. Started Apr 2017; status: terminated.
02
Drugs
tofacitinib oral solution
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT03159936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159936.